Stay updated on DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial page
- Check3 days agoChange DetectedThe ClinicalTrials.gov page displays the study record for the melanoma trial, including its study details, eligibility criteria, outcomes, and documents.SummaryDifference71%

- Check10 days agoChange DetectedThe study page displays a 403 Forbidden message, and the site revision label changes from v3.7.2 to v3.8.0.SummaryDifference0.6%

- Check17 days agoChange DetectedA site-wide NIH notice appears above the page, announcing updates and explaining that NIH content may use “Super Intelligence” in place of “Artificial Intelligence” during a transition.SummaryDifference1%

- Check24 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check31 days agoChange DetectedThe site footer now displays revision v3.7.1 instead of v3.7.0; the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check45 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the expected study record and indicating that access to the entry is blocked.SummaryDifference0.5%

Stay in the know with updates to DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial page.